Acute myeloid leukaemia
RecruitingStudy on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy
- Disease:Acute myeloid leukaemia
- Substances:AzacitidineIvosidenib+1
Germany- Participants:18–64 years · 65+ years
- Substances:Azacitidine
- Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting










